The Gastrointestinal Pathology Study Group of Korean Society of Pathologists, Jin Hee Sohn, Mee-Yon Cho, Yangsoon Park, Hyunki Kim, Woo Ho Kim, Joon Mee Kim, Eun Sun Jung, Kyoung-Mee Kim, Jae Hyuk Lee, Hee Kyung Chan, Do Youn Park, Mee Joo, Sujin Kim, Woo Sung Moon, Mi Seon Kang, So-Young Jin, Yun Kyung Kang, Sun Och Yoon, HyeSeung Han, EunHee Choi
Cancer Res Treat. 2015;47(4):813-822. Published online February 26, 2015
Purpose In 2010, the World Health Organization categorized L-cell type neuroendocrine tumors (NETs) as tumors of uncertain malignancy, while all others were classified as malignant. However, the diagnostic necessity of L-cell immunophenotyping is unclear, as are tumor stage and grade that may guide diagnosis and management. To clarify the predictive markers of rectal neuroendocrine neoplasms (NENs), 5- and 10-year overall survival (OS) was analyzed by pathological parameters including L-cell phenotype. Materials and Methods A total of 2,385 rectal NENs were analyzed from our previous multicenter study and a subset of 170 rectal NENs was immunophenotyped.
Results In univariate survival analysis, tumor grade (p < 0.0001), extent (p < 0.0001), size (p < 0.0001), lymph node metastasis (p=0.0063), and L-cell phenotype (p < 0.0001) showed significant correlation with the prognosis of rectal NENs; however, none of these markers achieved independent significance in multivariate analysis. The 10-year OS of tumors of NET grade 1, < 10 mm, the mucosa/submucosa was 97.58%, 99.47%, and 99.03%, respectively. L-Cell marker, glucagon II (GLP-1&2), with a cut off score of > 10, is useful in defining L-Cell type. In this study, an L-cell immunophenotype was found in 83.5% of all rectal NENs and most, but not all L-cell type tumors were NET G1, small (< 10 mm) and confined to the mucosa/submucosa. Conclusion From these results, the biological behavior of rectal NENs does not appear to be determined by L-cell type alone but instead by a combination of pathological parameters.
Citations
Citations to this article as recorded by
Is There a Relationship between the Staining Pattern of Classical Neuroendocrine Markers and Clinicopathological Findings in Neuroendocrine Tumors of the Appendix? Merve CİN, Enver YARIKKAYA, Selçuk CİN, Özgecan GÜNDOĞAR Bezmialem Science.2025; 13(1): 65. CrossRef
Extended Hormone Profiling Identifies a Wider Network of Duodenal Neuroendocrine Tumor Subtypes Luvy Delfin, Shereen Ezzat, Sylvia L. Asa Endocrine Pathology.2025;[Epub] CrossRef
Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors Joo Young Kim, Jisup Kim, Yong-il Kim, Dong-Hoon Yang, Changhoon Yoo, In Ja Park, Baek-Yeol Ryoo, Jin-Sook Ryu, Seung-Mo Hong Scientific Reports.2024;[Epub] CrossRef
The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors Ozgur Mete, David W. Dodington, Daniel L. Shen, Sylvia L. Asa Endocrine Pathology.2024; 35(2): 107. CrossRef
Cauda Equina Neuroendocrine Tumors Sylvia L. Asa, Ozgur Mete, Ulrich Schüller, Biswarathan Ramani, Kanish Mirchia, Arie Perry American Journal of Surgical Pathology.2023; 47(4): 469. CrossRef
Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future Stefano La Rosa Endocrine Pathology.2023; 34(1): 79. CrossRef
Clinicopathologic Impact of Peptide Hormonal Expression in Rectal Neuroendocrine Tumors Jisup Kim, Dong-Hoon Yang, HaeSung Jung, HyungJun Cho, Hyeung-Jin Jang, Changhoon Yoo, In Ja Park, Baek-Yeol Ryoo, Jin-Sook Ryu, Seung-Mo Hong Archives of Pathology & Laboratory Medicine.2023; 147(7): 797. CrossRef
Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation? Jack Cope, Raj Srirajaskanthan Current Oncology Reports.2022; 24(3): 257. CrossRef
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms Guido Rindi, Ozgur Mete, Silvia Uccella, Olca Basturk, Stefano La Rosa, Lodewijk A. A. Brosens, Shereen Ezzat, Wouter W. de Herder, David S. Klimstra, Mauro Papotti, Sylvia L. Asa Endocrine Pathology.2022; 33(1): 115. CrossRef
Rectal neuroendocrine neoplasms: what the radiologists should know Mayur Virarkar, Dheeraj R. Gopireddy, Ajaykumar C. Morani, Ahmad Alkhasawneh, Sergio Piotr Klimkowski, Sindhu Kumar, Chandana Lall, Priya Bhosale Abdominal Radiology.2022; 47(12): 4016. CrossRef
Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines Amr Mohamed, Sulin Wu, Mohamed Hamid, Amit Mahipal, Sakti Cjakrabarti, David Bajor, J. Eva Selfridge, Sylvia L. Asa Cancers.2022; 15(1): 295. CrossRef
Composite intestinal adenoma-microcarcinoid: An update and literature review Zhi-Yan Fu, Michel Kmeid, Mahmoud Aldyab, Stephen M Lagana, Hwajeong Lee World Journal of Gastrointestinal Endoscopy.2021; 13(12): 593. CrossRef
Classification of neuroendocrine neoplasms: lights and shadows Stefano La Rosa, Silvia Uccella Reviews in Endocrine and Metabolic Disorders.2021; 22(3): 527. CrossRef
Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification Sylvia L. Asa, Ozgur Mete, Michael D. Cusimano, Ian E. McCutcheon, Arie Perry, Shozo Yamada, Hiroshi Nishioka, Olivera Casar-Borota, Silvia Uccella, Stefano La Rosa, Ashley B. Grossman, Shereen Ezzat, International Pituitary Pathology, Sofia Asioli, Sühe Modern Pathology.2021; 34(9): 1634. CrossRef
Middle Ear “Adenoma”: a Neuroendocrine Tumor with Predominant L Cell Differentiation Sylvia L. Asa, Knarik Arkun, Arthur S. Tischler, Adnan Qamar, Fang-Ming Deng, Bayardo Perez-Ordonez, Ilan Weinreb, Justin A. Bishop, Bruce M. Wenig, Ozgur Mete Endocrine Pathology.2021; 32(4): 433. CrossRef
Chromogranin A Expression in Rectal Neuroendocrine Tumors Is Associated With More Aggressive Clinical Behavior and a Poorer Prognosis Jisup Kim, Joo Young Kim, Eun Hye Oh, Changhoon Yoo, In Ja Park, Dong-Hoon Yang, Baek-Yeol Ryoo, Jin-Sook Ryu, Seung-Mo Hong American Journal of Surgical Pathology.2020; 44(11): 1496. CrossRef
Endoscopic, transanal, laparoscopic, and transabdominal management of rectal neuroendocrine tumors Louis de Mestier, Diane Lorenzo, Caroline Fine, Jérôme Cros, Olivia Hentic, Thomas Walter, Yves Panis, Anne Couvelard, Guillaume Cadiot, Philippe Ruszniewski Best Practice & Research Clinical Endocrinology & Metabolism.2019; 33(5): 101293. CrossRef
Novel Finding of Paired Box 5 (PAX5) Cytoplasmic Staining in Well-differentiated Rectal Neuroendocrine Tumors (Carcinoids) and Its Diagnostic and Potentially Prognostic Utility Zhiyan Fu, Chunlai Zuo, Christine E. Sheehan, Deepa T. Patil, Jingmei Lin, Zhaohai Yang, Hwajeong Lee Applied Immunohistochemistry & Molecular Morphology.2019; 27(6): 454. CrossRef
Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms Günter Klöppel, Stefano La Rosa Virchows Archiv.2018; 472(3): 341. CrossRef
Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms Silvia Uccella, Stefano La Rosa, Marco Volante, Mauro Papotti Endocrine Pathology.2018; 29(2): 150. CrossRef
Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers Kai Duan, Ozgur Mete Cancer Cytopathology.2016; 124(12): 871. CrossRef
Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts Joo Young Kim, Seung-Mo Hong Archives of Pathology & Laboratory Medicine.2016; 140(5): 437. CrossRef